| Literature DB >> 34150939 |
Miguel Hueso1, Adrián Mallén2, Elia Ripoll2, Laura de Ramón2, Núria Bolaños2, Cristian Varela2, Jordi Guiteras2, Javier Checa3, Estanislao Navarro4, Josep Maria Grinyo5, Josep Maria Cruzado1,5, Josep Maria Aran3, Joan Torras1,5.
Abstract
The co-stimulatory molecule CD40 and its ligand CD40L play a key role in the regulation of immunological processes and are involved in the pathophysiology of autoimmune and inflammatory diseases. Inhibition of the CD40-CD40L axis is a promising therapy, and a number of strategies and techniques have been designed to hinder its functionality. Our group has broad experience in silencing CD40 using RNAi technology, and here we summarize protocols for the systemic administration of a specific anti-CD40 siRNA in different rodents models, in addition to the subsequent quantification of CD40 expression in murine kidneys by immunostaining. The use of RNAi technology with specific siRNAs to silence genes is becoming an essential method to investigate gene functions and is rapidly emerging as a therapeutic tool. Graphic abstract: CD40 siRNA mechanism.Entities:
Keywords: CD40; CD40L; Cholesterol-derived oligonucleotide; Kidney; Off-target effects; siRNA; siRNA therapy
Year: 2021 PMID: 34150939 PMCID: PMC8187154 DOI: 10.21769/BioProtoc.4032
Source DB: PubMed Journal: Bio Protoc ISSN: 2331-8325